Research Papers:
Loss of PIG3 increases HIF-1α level by promoting protein synthesis via mTOR pathway in renal cell carcinoma cells
Metrics: PDF 1662 views | HTML 2071 views | ?
Abstract
Guang Chen1,2,*, Jin-Ye Xu3,4,*, Jie Chen5, Jian-Xin Zhang5, Jun Zhou5, Yong Liang4,5 and Xiao-Fei Ding5
1 School of Pharmaceutical and Chemical Engineering, Taizhou University, Taizhou, Zhejiang, China
2 Institute of Tumor, Taizhou University, Taizhou, Zhejiang, China
3 Laboratory of Cancer Biology, Provincial Key Lab of Biotherapy in Zhejiang, Sir Runrun Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China
4 Taizhou Municipal Hospital, Taizhou, Zhejiang, China
5 School of Medicine, Taizhou University, Taizhou, Zhejiang, China
* These authors have contributted equally to this work
Correspondence to:
Xiao-Fei Ding, email:
Keywords: PIG3, HIF-1α, mTOR, renal cell carcinoma, migration
Received: August 24, 2015 Accepted: March 16, 2016 Published: March 27, 2016
Abstract
PIG3 is a target of the tumor suppressor p53 and is thought to be involved in p53-mediated cell apoptosis. Although PIG3 is similar to oxidoreductases involved in generating ROS, whether PIG3 would regulate HIF-1α was never characterized directly. Here we demonstrated that knockdown of PIG3 by transfecting with specific siRNA could increase the expression of HIF-1α in several human cancer cell lines, including CAKI, FTC-133 and A549. It indicates that PIG3 may be involved in the regulation of HIF-1α. Furthermore, we revealed that PIG3-siliencing increased HIF-1α protein level through promoting its protein biosynthesis via mTOR pathway. In addition, the effect of PIG3 on the production of HIF-1α was further related to VEGF secretion and cell migration. PIG3-downregulation increased the secretion of VEGF and promoted the migration of renal cancer cells obviously. Taken together, these data suggest that PIG3 was involved in HIF-1α regulation, and reveal a novel signaling pathway of PIG3/HIF-1α in the regulation of cell migration in renal cell carcinoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8401